Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic

Table 2

Bronchoalveolar lavage results.

	SARS-CoV-2 positive ()	SARS-CoV-2 negative ()
Pathogens
SARS-CoV-2	13 (93%)	0
Other pathogens	1 (7%)	23 (56%)
Bacteria	1 (7%)	14 (34%)
Streptococcus pneumoniae	0	2 (5%)
Streptococcus constellatus	0	1 (2%)
Haemophilus pneumoniae	0	3 (7%)
Serratia marcescens	1 (7%)	0
Escherichia coli	0	2 (5%)
Acinetobacter baumanii	0	1 (2%)
Prevotella sp.	0	1 (2%)
Chlamydia pneumoniae	0	2 (5%)
Mycoplasma pneumoniae	0	1 (2%)
Pneumocystis jirovecii	0	1 (2%)
Mycobacterium tuberculosis	0	1 (2%)
Virus	0	7 (17%)
Influenza A	0	4 (10%)
Metapneumovirus	0	1 (2%)
Adenovirus	0	1 (2%)
Herpes simplex virus		1 (2%)
Fungi	0	1 (2%)
Aspergillus fumigatus	0	1 (2%)^†
No pathogen	0	18 (44%)
Outcome at 4 weeks after BAL
Death	1 (7%)	4 (10%)
ICU	3 (21%)	0
6 (43%)	0	SARS-CoV-2-dedicated unit hospitalisation
1 (7%)	5 (12%)	Ward hospitalisation
Discharged	3 (21%)	32 (78%)

for comparisons between SARS-CoV-2-positive and negative patients. ^†Galactomannan value: 6. Abbreviations: BAL—bronchoalveolar lavage; ICU—intensive care unit.